Prasugrel: Clinical Trials

28 trials of Prasugrel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed, 3 unknown, 2 recruiting, 1 terminated. 28 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 328Completed 22, Unknown 3, Recruiting 2, Terminated 1
Phase 22Completed 1, Unknown 1

Follow Prasugrel: new trials by email Literature Review of Prasugrel trials Research Report on Prasugrel

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Clopidogrel, Ticagrelor, Prasugrel - Coronary Artery Disease, Percutaneous Coronary Intervention
Phase 3RecruitingCardiocentro Ticino3552026-04-202026-05-13
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
Clopidogrel - Coronary Artery Disease, Platelet Reactivity
Phase 2 / Phase 3UnknownSt. Antonius Hospital802023-04-262023-06-02
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Edoxaban, Clopidogrel, Prasugrel - Atrial Fibrillation
Phase 3CompletedDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company15062017-02-242020-05-06
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic)
Phase 3RecruitingUMC Utrecht200002016-04-112026-11-04
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome
Prasugrel, Clopidogrel - Acute Coronary Syndrome, Unstable Angina
Phase 3CompletedUniversity of Cologne492014-10-012015-06-11
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
Prasugrel, Clopidogrel - Acute Coronary Syndromes
Phase 3CompletedDong-A University702013-10-012019-02-11
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg - Atrial Fibrillation, Percutaneous Coronary Intervention
Phase 3CompletedJanssen Scientific Affairs, LLC21242013-05-102017-09-19
PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
ticagrelor, prasugrel - ST-Elevation Myocardial Infarction
Phase 3CompletedGennaro Sardella502013-05-012017-06-28
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
Prasugrel, Placebo - Sickle Cell Disease
Phase 3TerminatedEli Lilly and Company3412013-04-012019-09-25
Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome
Clopidogrel, Prasugrel - Coronary Artery Disease
Phase 3UnknownGennaro Sardella682013-03-012013-01-29
Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Prasugrel, Placebo - Coronary Artery Bypass
Phase 3CompletedVA Office of Research and Development842013-02-012019-10-30
Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
Prasugrel, Clopidogrel - Acute Coronary Syndrome
Phase 3CompletedDong-A University762012-09-012014-12-23
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
Clopidogrel, Prasugrel, Ticagrelor - Coronary Artery Disease
Phase 3CompletedUniversity of Roma La Sapienza812012-07-012013-12-11
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
Clopidogrel, prasugrel - Acute Coronary Syndrome
Phase 3CompletedGennaro Sardella302011-10-012012-03-27
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
Point-of-Care Genetic Testing, Prasugrel - STEMI
Phase 2 / Phase 3CompletedOttawa Heart Institute Research Corporation1022011-09-012013-04-25
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
PRASUGREL, Clopidogrel - Acute Coronary Syndromes
Phase 3CompletedAssistance Publique Hopitaux De Marseille1872011-07-012012-05-23
Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
Prasugrel, Clopidogrel - Myocardial Infarction, STEMI
Phase 3CompletedStiftung Institut fuer Herzinfarktforschung632011-05-012016-06-17
Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
Prasugrel, Ticagrelor - Coronary Artery Disease, Acute Coronary Syndrome
Phase 3CompletedUniversity of Patras442011-05-012012-06-22
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
Aspirin, Tirofiban, Clopidogrel - Coronary Artery Disease
Phase 3UnknownPrince Sultan Cardiac Center, Adult Cardiology Department.2002011-04-012012-05-15
Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)
Prasugrel, Clopidogrel - Myocardial Infarction
Phase 3CompletedUniversity of Patras352011-04-012011-09-30

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Acute Coronary Syndrome (13)  ·  Coronary Artery Disease (9)  ·  ST Elevation Myocardial Infarction (4)  ·  Atrial Fibrillation (2)  ·  Myocardial Infarction (2)  ·  Anemia, Sickle Cell (1)  ·  Angina, Stable (1)  ·  Angina, Unstable (1)  ·  Arrhythmias, Cardiac (1)  ·  COVID-19 (1)  ·  Community-Acquired Pneumonia (1)  ·  Diabetes Mellitus (1)  ·  Heart Diseases (1)  ·  Influenza, Human (1)  ·  Insulin Resistance (1)

Sponsors

Eli Lilly and Company (5)  ·  University of Patras (5)  ·  Gennaro Sardella (3)  ·  Dong-A University (2)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Cardiocentro Ticino (1)  ·  Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1)  ·  Janssen Scientific Affairs, LLC (1)  ·  Ottawa Heart Institute Research Corporation (1)  ·  Prince Sultan Cardiac Center, Adult Cardiology Department. (1)  ·  St. Antonius Hospital (1)  ·  Stiftung Institut fuer Herzinfarktforschung (1)  ·  UMC Utrecht (1)  ·  University of Cologne (1)  ·  University of Roma La Sapienza (1)

Countries

Italy (10)  ·  France (7)  ·  Germany (7)  ·  Belgium (6)  ·  Canada (6)  ·  Greece (6)  ·  Netherlands (6)  ·  South Korea (6)  ·  United States (6)  ·  Romania (5)  ·  United Kingdom (5)  ·  Czechia (4)  ·  Hungary (4)  ·  Poland (4)  ·  Portugal (4)

Top investigators

Moo Hyun Kim, MD (2)  ·  Andreas Gotte, Prof., MD (1)  ·  Colin McArthur, Dr (1)  ·  Derek Angus, Prof (1)  ·  Derek Y F So, MD (1)  ·  Hussein S Al-Amri, MD (1)  ·  Jason D Roberts, MD (1)  ·  John Marshall, Prof (1)  ·  Lennie Derde, MD (1)

Results publications

PMID 35224730, PMID 17982182, PMID 18377975, PMID 18498956, PMID 18757948, PMID 19106084, PMID 19249633, PMID 19699846, PMID 20026770, PMID 20598967, PMID 20723851, PMID 21473962, PMID 21511219, PMID 21606391, PMID 22199016, PMID 22440491, PMID 22633653, PMID 22783896, PMID 22789884, PMID 22920930, PMID 22995726, PMID 23048056, PMID 23117779, PMID 23448344, PMID 23953385, PMID 23991622, PMID 24140678, PMID 24947719, PMID 24952863, PMID 25012156, PMID 25524333, PMID 25538134, PMID 25616919, PMID 25819853, PMID 26011265, PMID 26060122, PMID 26089177, PMID 26386793, PMID 26542513, PMID 26637834, PMID 26644172, PMID 26883498, PMID 26916483, PMID 26988949, PMID 27030601, PMID 27151605, PMID 27517654, PMID 27815268, PMID 27881555, PMID 27959713

NIH funding

2015 (1), 2016 (1), 2023 (1)